Antiphospholipase A2 Receptor Autoantibodies: A Step Forward in the Management of Primary Membranous Nephropathy

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Obrisca, Bogdan ^a   Ismail, Gener ^a   Jurubita, Roxana ^b   Baston, Catalin ^b   Andronesi, Andreea ^a   Mircescu, Gabriel ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b FUNDENI CLINICAL INSTITUTE   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; PHOSPHOLIPASE A2 RECEPTOR; PHOSPHOLIPASE A2 RECEPTOR ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ARTICLE; DISEASE COURSE; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; MEMBRANOUS GLOMERULONEPHRITIS; MOLECULAR PATHOLOGY; NONHUMAN; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; ANIMAL; ANTAGONISTS AND INHIBITORS; EVIDENCE BASED MEDICINE; GLOMERULONEPHRITIS, MEMBRANOUS; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; EVIDENCE-BASED MEDICINE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, PHOSPHOLIPASE A2;

EID: 84947276028     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/249740     Document Type: Article

References (61)

1. G. L. Braden, J. G. Mulhern, M. H. OShea, S. V. Nash, A. A. Ucci Jr., andM. J. Germain, "Changing incidence of glomerular diseases in adults, " American Journal of Kidney Diseases, vol. 35, no. 5, pp. 878-883, 2000.
2. S. Swaminathan, N. Leung, D. J. Lager et al., "Changing incidence of glomerular disease in Olmsted County, Minnesota: A 30-year renal biopsy study, " Clinical journal of the American Society of Nephrology, vol. 1, no. 3, pp. 483-487, 2006.
3. M. Bahiense-Oliveira, L. B. Saldanha, E. L. Andrade Mota, D. Oliveira Penna, R. Toledo Barros, and J. E. Romão-Junior, "Primary glomerular diseases in Brazil (1979-1999): is the frequency of focal and segmental glomerulosclerosis increasing?" Clinical Nephrology, vol. 61, no. 2, pp. 90-97, 2004.
4. D. Dragovic, J. L. Rosenstock, S. J. Wahl, G. Panagopoulos, M. V. DeVita, and M. F. Michelis, "Increasing incidence of focal segmental glomerulosclerosis and an examination of demographic patterns, " Clinical Nephrology, vol. 63, no. 1, pp. 1-7, 2005.
5. M. Haas, S. M. Meehan, T. G. Karrison, and B. H. Spargo, "Changing etiologies of unexplained adult nephrotic syndrome: A comparison of renal biopsy findings from 1976-1979 and 1995-1997, " American Journal of Kidney Diseases, vol. 30, no. 5, pp. 621-631, 1997.
6. S. R. Orth and E. Ritz, "The nephrotic syndrome, " The New England Journal ofMedicine, vol. 338, no. 17, pp. 1202-1211, 1998.
7. S. M. Korbet, R.M. Genchi, R. Z. Borok, andM.M. Schwartz, "The racial prevalence of glomerular lesions in nephrotic adults, " American Journal of Kidney Diseases, vol. 27, no. 5, pp. 647-651, 1996.
8. F. Rivera, J. M. Ĺopez-Gomez, and R. Perez-Garćia, "Clinicopathologic correlations of renal pathology in Spain, " Kidney International, vol. 66, no. 3, pp. 898-904, 2004.
9. H. A. Austin III, T. T. Antonovych, K. MacKay, D. T. Boumpas, and J. E. Balow, "Membranous nephropathy, " Annals of Internal Medicine, vol. 116, no. 8, pp. 672-682, 1992.
10. L. H. Beck Jr., R. G. B. Bonegio, G. Lambeau et al., "M-Type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy, " The New England Journal of Medicine, vol. 361, no. 1, pp. 11-21, 2009.
11. N. M. Tomas, L. H. Beck, C. Meyer-Schwesinger et al., "Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy, " The New England Journal of Medicine, vol. 371, no. 24, pp. 2277-2287, 2014.
12. L. East and C. M. Isacke, "The mannose receptor family, " Biochimica et Biophysica Acta: General Subjects, vol. 1572, no. 2-3, pp. 364-386, 2002.
13. O. Llorca, "Extended and bent conformations of the mannose receptor family, " Cellular andMolecular Life Sciences, vol. 65, no. 9, pp. 1302-1310, 2008.
14. J. Boskovic, J. N. Arnold, R. Stilion et al., "Structural model for themannose receptor family uncovered by electron microscopy of Endo180 and themannose receptor, " The Journal of Biological Chemistry, vol. 281, no. 13, pp. 8780-8787, 2006.
15. K. Hanasaki and H. Arita, "Phospholipase A2 receptor: A regulator of biological functions of secretory phospholipaseA2, " Prostaglandins and Other LipidMediators, vol. 68-69, pp. 71-82, 2002.
16. E. Zvaritch, G. Lambeau, and M. Lazdunski, "Endocytic properties of the M-Type 180-kDa receptor for secretory phospholipases A2, " The Journal of Biological Chemistry, vol. 271, no. 1, pp. 250-257, 1996.
17. G. Lambeau, P. Ancian, J.-P. Nicolas et al., "Structural elements of secretory phospholipases A2 involved in the binding to Mtype receptors, " The Journal of Biological Chemistry, vol. 270, no. 10, pp. 5534-5540, 1995.
18. L. Kao, V. Lam, M. Waldman, R. J. Glassock, and Q. Zhu, "Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy, " Journal of the American Society of Nephrology, vol. 26, no. 2, pp. 291-301, 2015.
19. M. Fresquet, T. A. Jowitt, J. Gummadova et al., "Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy, " Journal of the American Society of Nephrology, vol. 26, no. 2, pp. 302-313, 2015.
20. M. J. H. Coenen, J. M. Hofstra, H. Debiec et al., "Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy, " Journal of the American Society of Nephrology, vol. 24, no. 4, pp. 677-683, 2013.
21. P. Ancian, G. Lambeau, M.-G. Mattei, and M. Lazdunski, "The human 180-kDa receptor for secretory phospholipases A2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization, " The Journal of Biological Chemistry, vol. 270, no. 15, pp. 8963-8970, 1995.
22. C. Ponticelli and R. J. Glassock, "Glomerular diseases: membranous nephropathy-A modern view, " Clinical Journal of the American Society of Nephrology, vol. 9, no. 3, pp. 609-616, 2014.
23. J. Lv, W. Hou, X. Zhou et al., "Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies andmembranous nephropathy, " Journal of the American Society of Nephrology, vol. 24, no. 8, pp. 1323-1329, 2013.
24. L. H. Beck, "The dominant humoral epitope in phospholipase A2 receptor-1: presentation matters when serving up a slice of, " Journal of the American Society of Nephrology, vol. 26, pp. 237-239, 2014.
25. H. C. Stanescu, M. Arcos-Burgos, A. Medlar et al., "Risk HLA-DQA1 and PLA2R1 alleles in idiopathic membranous nephropathy, " The New England Journal of Medicine, vol. 364, no. 7, pp. 616-626, 2011.
26. A. Kuroki, M. Iyoda, T. Shibata, andT. Sugisaki, "Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy, " Kidney International, vol. 68, no. 1, pp. 302-310, 2005.
27. K. Hirayama, I. Ebihara, S. Yamamoto et al., "Predominance of type-2 immune response in idiopathic membranous nephropathy: cytoplasmic cytokine analysis, " Nephron, vol. 91, no. 2, pp. 255-261, 2002.
28. P. G. Tipping and A. R. Kitching, "Glomerulonephritis, Th1 and Th2: whats new?" Clinical and Experimental Immunology, vol. 142, no. 2, pp. 207-215, 2005.
29. H. Imai, K. Hamai, A. Komatsuda, H. Ohtani, and A. B. Miura, "IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis, " Kidney International, vol. 51, no. 1, pp. 270-276, 1997.
30. K. Lhotta, R. Würzner, and P. König, "Glomerular deposition of mannose-binding lectin in human glomerulonephritis, " Nephrology Dialysis Transplantation, vol. 14, no. 4, pp. 881-886, 1999.
31. A. Roos, M. R. Daha, J. van Pelt, and S. P. Berger, "Mannosebinding lectin and the kidney, " Nephrology Dialysis Transplantation, vol. 22, no. 12, pp. 3370-3377, 2007.
32. H. Debiec, M. Hanoy, A. Francois et al., "Recurrent membranous nephropathy in an allograft caused by IgG3 targeting the PLA2 receptor, " Journal of the American Society of Nephrology, vol. 23, no. 12, pp. 1949-1954, 2012.
33. M. Schulze, J. V. Donadio Jr., C. J. Pruchno et al., "Elevated urinary excretion of the C5b-9 complex in membranous nephropathy, " Kidney International, vol. 40, no. 3, pp. 533-538, 1991.
34. S. P. Kon, B. Coupes, C. D. Short et al., "Urinary C5b-9 excretion and clinical course in idiopathic humanmembranous nephropathy, " Kidney International, vol. 48, no. 6, pp. 1953-1958, 1995.
35. A. V. Cybulsky, R. J. Quigg, and D. J. Salant, "Experimental membranous nephropathy redux, " American Journal of Physiology: Renal Physiology, vol. 289, no. 4, pp. F660-F671, 2005.
36. T. Takano, H. Elimam, and A. V. Cybulsky, "Complementmediated cellular injury, " Seminars in Nephrology, vol. 33, no. 6, pp. 586-601, 2013.
37. S. A. Timmermans, P. van Paassen, and J. W. Cohen Tervaert, "Recent advances in the understanding of immune-mediated nephrotic syndrome: diagnostic and prognostic implications, " Expert Review of Clinical Immunology, vol. 11, no. 4, pp. 489-500, 2015.
38. J. M. Hofstra, H. Debiec, C. D. Short et al., "Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy, " Journal of the American Society of Nephrology, vol. 23, no. 10, pp. 1735-1743, 2012.
39. J. M. Hofstra, L. H. Beck Jr., D. M. Beck, J. F. Wetzels, and D. J. Salant, "Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy, " Clinical Journal of the American Society of Nephrology, vol. 6, no. 6, pp. 1286-1291, 2011.
40. L. H. Beck Jr., F. C. Fervenza, D. M. Beck et al., "Rituximabinduced depletion of anti-PLA2R autoantibodies predicts response inmembranous nephropathy, " Journal of the American Society of Nephrology, vol. 22, no. 8, pp. 1543-1550, 2011.
41. E. Hoxha, S. Harendza, G. Zahner et al., "An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis, " Nephrology Dialysis Transplantation, vol. 26, no. 8, pp. 2526-2532, 2011.
42. D. Kanigicherla, J. Gummadova, E. A. McKenzie et al., "Anti-PLA2R antibodies measured by ELISA predict long-Term outcome in a prevalent population of patients with idiopathic membranous nephropathy, " Kidney International, vol. 83, no. 5, pp. 940-948, 2013.
43. Y. J. Oh, S. H. Yang, D. K. Kim, S.-W. Kang, and Y. S. Kim, "Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy, " PLoS ONE, vol. 8, no. 4, Article ID e62151, 2013.
44. B. Svobodova, E. Honsova, P. Ronco, V. Tesar, and H. Debiec, "Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-relatedmembranous nephropathy, " Nephrology Dialysis Transplantation, vol. 28, no. 7, pp. 1839-1844, 2013.
45. A.P. Bech, J.M. Hofstra, P. E. Brenchley, and J.F. Wetzels, "Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy, " Clinical Journal of the American Society of Nephrology, vol. 9, no. 8, pp. 1386-1392, 2014.
46. E. Hoxha, I. Thiele, G. Zahner, U. Panzer, S. Harendza, and R. A. K. Stahl, "Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy, " Journal of theAmericanSociety ofNephrology, vol. 25, no. 6, pp. 1357-1366, 2014.
47. A. Segarra-Medrano, E. Jatem-Escalante, C. Carnicer-Ćaceres et al., "Evolution of antibody titre against the M-Type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus, " Nefrologia, vol. 34, no. 4, pp. 491-497, 2014.
48. C. Murtas, M. Bruschi, G. Candiano et al., "Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy, " Clinical Journal of the American Society of Nephrology, vol. 7, no. 9, pp. 1394-1400, 2012.
49. G. Mastroianni-Kirsztajn, N. Hornig, and W. Schlumberger, "Autoantibodies in renal diseases-clinical significance and recent developments in serological detection, " Frontiers in Immunology, vol. 6, article 221, 2015.
50. T. Stehĺe, V. Audard, P. Ronco, and H. Debiec, "Phospholipase A2 receptor and sarcoidosis-Associated membranous nephropathy, " Nephrology Dialysis Transplantation, vol. 30, no. 6, pp. 1047-1050, 2015.
51. A. Khosroshahi, R. Ayalon, L. H. Beck Jr., D. J. Salant, D. B. Bloch, and J. H. Stone, "IgG4-related disease is not associated with antibody to the phospholipase A2 receptor, " International Journal of Rheumatology, vol. 2012, Article ID 139409, 6 pages, 2012.
52. M. A. Hladunewich, S. Troyanov, J. Calafati, and D. C. Cattran, "The natural history of the non-nephrotic membranous nephropathy patient, " Clinical Journal of the American Society of Nephrology, vol. 4, no. 9, pp. 1417-1422, 2009.
53. E. P. McQuarrie, C. M. Stirling, and C. C. Geddes, "Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of evidence-based therapy, " Nephrology Dialysis Transplantation, vol. 27, no. 1, pp. 235-242, 2012.
54. Glomerulonephritis Work Group, "KDIGO clinical practice guideline for glomerulonephritis, " Kidney International Supplements, vol. 2, no. 2, pp. 1-274, 2012.
55. D. C. Cattran, Y. Pei, C. M. T. Greenwood, C. Ponticelli, P. Passerini, and E. Honkanen, "Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications, " Kidney International, vol. 51, no. 3, pp. 901-907, 1997.
56. J. M. Hofstra and J. F. Wetzels, "Anti-PLA(2)R antibodies in membranous nephropathy: ready for routine clinical practice?" Netherlands Journal ofMedicine, vol. 70, no. 3, pp. 109-113, 2012.
57. R. J. Glassock, "Antiphospholipase A2 receptor autoantibody guided diagnosis and treatment of membranous nephropathy: A new personalized medical approach, " Clinical Journal of the American Society ofNephrology, vol. 9, no. 8, pp. 1341-1343, 2014.
58. L. H. Beck Jr. andD. J. Salant, "Membranous nephropathy: from models to man, " Journal of Clinical Investigation, vol. 124, no. 6, pp. 2307-2314, 2014.
59. E. Hoxha, S. Harendza, H. Pinnschmidt, U. Panzer, and R. A. K. Stahl, "PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the reninangiotensin system, " PLoSONE, vol. 9, no. 10, Article IDe110681, 2014.
60. A. Kattah, R. Ayalon, L. H. Beck Jr. et al., "Anti-phospholipase A2 receptor antibodies in recurrent membranous nephropathy, " American Journal of Transplantation, vol. 15, no. 5, pp. 1349-1359, 2015.
61. S.-L. Hu, D. Wang, W.-J. Gou, Q.-F. Lei, T.-A. Ma, and J.-Z. Cheng, "Diagnostic value of phospholipase A2 receptor in idiopathic membranous nephropathy: A systematic review and meta-Analysis, " Journal of Nephrology, vol. 27, no. 2, pp. 111-116, 2014.